Xenotransplantation, the futuristic-sounding field of animal-to-human organ transplants, is suddenly a lot closer to reality. The first two gene-edited pig kidneys have been transplanted into humans — and, so far, seem to be working beautifully.
It is an astonishing advance in a field that has languished for years. It is also priming a race between companies in the field.
Who will be first to convince the world their technologies are the most viable?
Last year, researchers offered evidence that these pig organs could work in the long term — in monkeys, at least. One monkey lived for two years after receiving an organ developed by eGenesis, a biotech firm cofounded by Harvard bioengineer George Church. That added to several studies suggesting pig organs were functional for short stints when transplanted into brain-dead people who had donated their bodies to science.
Then last month, eGenesis provided a kidney to Richard Slayman. After being treated for an early sign of rejection, he was able to leave Massachusetts General Hospital, whose surgeons performed the transplant, just two weeks later.
It was a stunning turnaround for the 62-year-old Massachusetts man, who had four years earlier received a human kidney that was failing.
Due to a raft of other health problems, he had just a 16 percent chance of getting a transplant within the following five years, said one of his doctors, Winfred Williams, associate chief of the hospital’s nephrology division.
Now we have got a second success story, this time with a pig kidney developed by United Therapeutics Corp.
Like Slayman, New Jersey resident Lisa Pisano was “very ill and caught in a medical catch-22,” said Robert Montgomery, the director of the NYU Langone Transplant Institute, where the surgery was performed.
Pisano’s heart and kidney were failing, yet her other health conditions kept her off the organ donation list and although a medical device called a left ventricular assist device could have helped pump blood from her heart to the rest of her body, it has not been an option for someone on dialysis — the mortality rate is too high.
That left Pisano with weeks to live.
The 54-year-old became the first person ever to undergo a combined heart pump and pig kidney transplant. Nearly two weeks later, the organ seems to be working beautifully and she has shown no signs of rejecting it.
Talking to reporters via Zoom from her hospital bed, Pisano said: “I feel fantastic. I feel the best I’ve felt in a long time.”
Slayman’s and Pisano’s plights are faced by far too many people. They are too sick to be eligible for an organ donation, or one does not arrive in time, and on a more basic level, there just are not enough organs to go around.
According to the Organ Procurement and Transplant Network, nearly 90,000 people are waiting for a kidney.
Williams said that people with certain blood types might wait on average for six to seven years for a kidney — and too often one does not arrive in time.
The next few months will be an important test for whether pig kidneys can dispatch with those long waits. Doctors will be watching to see whether the patients’ immune systems continue to tolerate the organs.
They will also be watching whether one organ does better than the other. Slayman’s pig kidney features 69 edits, most of which are intended to turn off genes that might put him at risk of infection.
By contrast, the organ that Lisa Pisano received had just a single gene edit. It was intended to knock out a sugar sitting on the surface of pig cells that triggers an immune reaction.
Her kidney also had tissue from the pig’s thymus grafted to it, a modification intended to help train the recipient’s immune system to be tolerant of the pig kidney.
Ultimately, the hope is that the addition of the thymus allows recipients to be weaned from some of the powerful immunosuppressant drugs that follow transplants.
The two strategies (and others in development, including a pig kidney from United Therapeutics with 10 gene edits) have sparked a debate about whether less is more (or more is more) when it comes to gene edits intended to make these organs safer. The goal is to provide an organ that properly functions, while minimizing the risks of rejection and maximizing long-term safety.
The next step will be clinical trials. Williams believes that if Slayman’s pig kidney keeps him stable and continues to look safe over the next six months to a year, it is time for the US Food and Drug Administration to allow formal studies to move forward.
That is a sentiment echoed by United Therapeutics, which believes it might be allowed to start clinical trials of its pig kidneys next year.
No matter which technology wins — and I hope there is not just one winning strategy, but several — it is important to stay focused on the ultimate prize: a world where no one has to die waiting for a donor.
And of course, we cannot overlook the true pioneers here: Pisano and Slayman. It is no small thing to step up to be the first. While of course they were hoping for more time with their families, they knew there was a reasonable chance of a grimmer outcome. They also understand their important role in medical history.
As Pisano told reporters: “The worst-case scenario, if it doesn’t work, it might work for the next person.”
Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, healthcare and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News. This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.
On May 7, 1971, Henry Kissinger planned his first, ultra-secret mission to China and pondered whether it would be better to meet his Chinese interlocutors “in Pakistan where the Pakistanis would tape the meeting — or in China where the Chinese would do the taping.” After a flicker of thought, he decided to have the Chinese do all the tape recording, translating and transcribing. Fortuitously, historians have several thousand pages of verbatim texts of Dr. Kissinger’s negotiations with his Chinese counterparts. Paradoxically, behind the scenes, Chinese stenographers prepared verbatim English language typescripts faster than they could translate and type them
More than 30 years ago when I immigrated to the US, applied for citizenship and took the 100-question civics test, the one part of the naturalization process that left the deepest impression on me was one question on the N-400 form, which asked: “Have you ever been a member of, involved in or in any way associated with any communist or totalitarian party anywhere in the world?” Answering “yes” could lead to the rejection of your application. Some people might try their luck and lie, but if exposed, the consequences could be much worse — a person could be fined,
Xiaomi Corp founder Lei Jun (雷軍) on May 22 made a high-profile announcement, giving online viewers a sneak peek at the company’s first 3-nanometer mobile processor — the Xring O1 chip — and saying it is a breakthrough in China’s chip design history. Although Xiaomi might be capable of designing chips, it lacks the ability to manufacture them. No matter how beautifully planned the blueprints are, if they cannot be mass-produced, they are nothing more than drawings on paper. The truth is that China’s chipmaking efforts are still heavily reliant on the free world — particularly on Taiwan Semiconductor Manufacturing
Keelung Mayor George Hsieh (謝國樑) of the Chinese Nationalist Party (KMT) on Tuesday last week apologized over allegations that the former director of the city’s Civil Affairs Department had illegally accessed citizens’ data to assist the KMT in its campaign to recall Democratic Progressive Party (DPP) councilors. Given the public discontent with opposition lawmakers’ disruptive behavior in the legislature, passage of unconstitutional legislation and slashing of the central government’s budget, civic groups have launched a massive campaign to recall KMT lawmakers. The KMT has tried to fight back by initiating campaigns to recall DPP lawmakers, but the petition documents they
RSS